The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study

Keller, Martin B.; Trivedi, Madhukar H.; Thase, Michael E.; Shelton, Richard C.; Kornstein, Susan G.; Nemeroff, Charles B.; Friedman, Edward S.; Gelenberg, Alan J.; Kocsis, James H.; Dünner, David L.; Hirschfeld, Robert M. A.; Rothschild, Anthony J.; Ferguson, James M.; Schatzberg, Alan F.; Zajecka, John; Pedersen, Ronald; Yan, Bing Chun; Ahmed, Saeeduddin; Musgnung, Jeff; Ninan, Philip T.

doi:10.4088/jcp.v68n0812

Cited by 94 publications

(61 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For our patients with MDD, the CDS analyses by Judd and colleagues 12 indicate the need to pursue treatment until achieving an asymptomatic state in order to maximize long-term outcomes. Combined with data from other studies, 18,19 the low rates of antidepressant treatment and high rates of recurrence in the CDS sample, even among those with asymptomatic recovery, indicate that our sicker patients are very likely to need long-term maintenance therapy in order to stay well.…”

mentioning

confidence: 62%

“…Clinicians could discuss the patient's status as "remission without recovery" just as the phrasing "response without remission" is used today. There are now a large number of trials [20][21][22][23][24][25] that have conducted long-term (≥ 1 year) follow-up of patients who completed a period of acute treatment. The time is ripe for the owners of these and other datasets to finally embark on a concerted and coordinated analytic effort to empirically define the optimal symptom severity and duration thresholds for recovery from MDD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

When Should a Patient Be Declared Recovered From a Major Depressive Episode?

Dunlop¹,

Rapaport²

2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 62%

mentioning

confidence: 99%

When Should a Patient Be Declared Recovered From a Major Depressive Episode?

Dunlop¹,

Rapaport²

2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Studies suggest that the SNRI venlafaxine extended release (ER) is no more likely than SSRIs to cause weight gain in the short term and that significant weight changes are no more common with maintenance treatment with venlafaxine ER (up to 2years) than with placebo. [16][17][18] Desvenlafaxine was not associated with clinically significant weight change during short-or longer-term treatment. 19,20 Serum leptin and TNF-α in correlation to weight neutral antidepressants…”

Section: Obesity Parameters In Correlation To Weight Neutral Antideprmentioning

confidence: 93%

The relationship of serum leptin, serum TNF-α, plasma lipids and obesity parameters in patients treated with weight neutral antidepressants

et al. 2018

View full text Add to dashboard Cite

Background: Leptin and tumor necrosis factor (TNFα) are involved in weight regulation1. Elevated lipids are frequently encountered in obese people which are helpful in the formation of atherosclerotic plaques in the coronary arteries. This study helps us to know whether weight neutral antidepressant therapy can be therapeutic option in those with obesity associated with depression.Methods: It is a Longitudinal study of sample size 72 where Patients with obesity attending to JSS hospital who are found to be depressive in both inpatients and out patients fulfilling the inclusion and exclusion criteria.Results: Our study showed mean difference value of weight, BMI and waist circumference, S. leptin, S.TNF-α, S. total cholesterol, S. LDL-C, S. VLDL-C, triglycerides of obese patients treated with lifestyle modifications, psychotherapy and weight neutral antidepressants at baseline and 3rd month was significantly decreased when compared to obese patients treated with lifestyle modifications, psychotherapy alone at baseline and 3rd month is 3.5kgs, 1.2kg/m2, 0.89cm, 9.53pg/ml, 10.86pg/ml, 22.34mg/dl, 17.94mg/dl, 4.42mg/dl, 21.78mg/dl and 1.2kgs, 0.32kg/m2, 0.02cm, 5.22pg/ml, 7.86pg/ml, 11.72mg/dl, 15.37mg/dl, 1.98mg/dl, 9.54mg/dl respectively (p=0.0001).Conclusions: Our study demonstrated a significant weight loss, and significant decrease in S. Leptin, S. TNF- α, TC, LDL-C, VLDL-C, triglycerides, when obese patients treated with lifestyle modifications, psychotherapy and weight neutral antidepressant (Desvenlafaxine).

show abstract

“…Painful physical symptoms Painful physical symptoms (PPS) have been recognized as an integral part of depression and are associated with greater illness severity and poorer overall functioning [57,58]. Numerous studies in animals [59], as well in human subjects [60,61], have demonstrated agents that impact on both the serotonergic and noradrenergic neurotransmitter systems and affect the experience of painful symptoms to a greater extent than single action agents, possibly owing to their modulatory effects on descending spinal pain pathways [62].…”

Section: Drug Profilementioning

confidence: 99%

Duloxetine in the acute and continuation treatment of major depressive disorder

Bochsler

Olver

Norman

2011

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Duloxetine is a serotonin-noradrenaline reuptake inhibitor with indications for use in the short term, continuation and maintenance treatment of major depression. Although clinicians currently have access to a range of medications for the treatment of depression, a significant number of patients fail to respond or remit from their illness despite adequate trials of treatment with multiple agents. A developing concept is that antidepressant strategies that combine multiple mechanisms of action may have advantages over agents with single mechanisms (i.e., selective serotonin reuptake inhibitors). As a dual-acting agent, duloxetine offers the promise of advantages in terms of efficacy over selective serotonin reuptake inhibitors while retaining a favorable safety and tolerability profile in comparison to older agents. Likewise, duloxetine is of interest in the treatment of certain conditions commonly seen in conjunction with major depression, particularly anxiety and pain, both of which may respond more favorably to agents that act on both serotonin and noradrenaline neurotransmitter systems.

show abstract

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study

Cited by 94 publications

References 28 publications

When Should a Patient Be Declared Recovered From a Major Depressive Episode?

When Should a Patient Be Declared Recovered From a Major Depressive Episode?

The relationship of serum leptin, serum TNF-α, plasma lipids and obesity parameters in patients treated with weight neutral antidepressants

Duloxetine in the acute and continuation treatment of major depressive disorder

Contact Info

Product

Resources

About